Correction to: Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme

被引：0
|
作者：
Nalee Kim
Joongyo Lee
Do-Hyun Nam
Jung-Il Lee
Ho Jun Seol
Doo-Sik Kong
Jung Won Choi
Kyuha Chong
Won Jae Lee
Jong Hee Chang
Seok-Gu Kang
Ju Hyung Moon
Jaeho Cho
Do Hoon Lim
Hong In Yoon
机构：
[1] Sungkyunkwan University School of Medicine,Department of Radiation Oncology, Samsung Medical Center
[2] Yonsei University College of Medicine,Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System
[3] Sungkyunkwan University School of Medicine,Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center
[4] Yonsei University College of Medicine,Department of Neurosurgery, Severance Hospital, Yonsei University Health System
[5] Yonsei University College of Medicine,Brain Tumor Center, Severance Hospital, Yonsei University Health System
[6] Yonsei University College of Medicine,Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei Cancer Center, Yonsei University Health System
来源：
Journal of Neuro-Oncology | 2023年 / 165卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 269
相关论文
共 35 条
  • [31] AN AMERICAN BRAIN TUMOR CONSORTIUM (ABTC) PHASE I TRIAL OF ABT-888 (VELIPARIB), TEMOZOLOMIDE (TMZ), AND CONCURRENT RADIOTHERAPY (RT) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): HEMATOLOGIC TOXICITY IS LIMITING.
    Kleinberg, Lawrence
    Blakeley, Jaishri
    Mikkelsen, Tom
    Stevens, Glenn
    Ye, Xiaobu
    Ryu, Sam
    Desideri, Serena
    Desai, Bhardwaj
    Giranda, Vincent
    Grossman, Stuart
    NEURO-ONCOLOGY, 2012, 14 : 102 - 102
  • [32] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Sul, J.
    Panageas, K. S.
    Lassman, A. B.
    Hormigo, A.
    Nolan, C.
    Gavrilovic, I. T.
    Grimm, S. A.
    DeAngelis, L. M.
    Abrey, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15)
    Padovan, M.
    De Salvo, G.
    Cerretti, G.
    Krengli, M.
    Caccese, M.
    Maccari, M.
    Farina, M.
    Bergo, E.
    Zabeo, C.
    Grosso, D.
    Caumo, F.
    Coppola, M.
    D'Avolio, A.
    Zagonel, V.
    Lombardi, G.
    NEURO-ONCOLOGY, 2023, 25
  • [34] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Clarke, Jennifer
    Sul, Joohee
    DeAngelis, Lisa
    Lassman, Andrew
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor
    Gu, Bin
    Panageas, Kathy
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [35] The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.
    Lombardi, Giuseppe
    Giunco, Silvia
    Cavallin, Francesco
    Angelini, Chiara
    Caccese, Mario
    Cerretti, Giulia
    De Bonis, Pasquale
    De Rossi, Anita
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
1234